<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>jmedicalcasereports</PublisherName>
      <JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
      <PISSN>I</PISSN>
      <EISSN>S</EISSN>
      <Volume-Issue>Volume 6; Issue 3</Volume-Issue>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season>(May-Jun, 2025)</Season>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>-0001</Year>
        <Month>11</Month>
        <Day>30</Day>
      </PubDate>
      <ArticleType>Medical Case Reports</ArticleType>
      <ArticleTitle>Mifepristone-Induced Hypokalemia Causing Rhabdomyolysis and Severe Acute Kidney Injury: A Case Report</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>1</FirstPage>
      <LastPage>10</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Houtz</FirstName>
          <LastName>BL</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Newman</FirstName>
          <LastName>ED</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Cuda</FirstName>
          <LastName>TL</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Kattel</FirstName>
          <LastName>G</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Farber</FirstName>
          <LastName>JL</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Filippone</FirstName>
          <LastName>EJ</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI/>
      <Abstract>Mifepristone is a glucocorticoid receptor (GR) blocker approved for improving glucose control in patients with endogenous Cushing’s Syndrome (CS) in whom surgical cure is contraindicated or has failed. Due to GR blockade, levels of ACTH and cortisol become markedly higher. When cortisol levels are sufficiently high, the enzyme conferring aldosterone specificity to the aldosterone-sensitive distal nephron, 11__ampersandsignbeta;-hydroxysteroid dehydrogenase type 2, that converts active cortisol to inactive cortisone may be overwhelmed. The result may be enhanced renal potassium excretion and hypokalemia. We report a case of a patient with suspected CS given mifepristone to improve glucose control. The patient subsequently presented with rhabdomyolysis and severe acute kidney injury (AKI) requiring emergency dialysis. Kidney biopsy confirmed myoglobinuria as the cause of the AKI. Despite ongoing cell breakdown, severely reduced GFR, dialysis against a high potassium bath, and daily potassium replacement, the serum potassium took days to normalize. We postulate that mifepristone-induced severe potassium deficiency with hypokalemia was the trigger for rhabdomyolysis and AKI in this patient. This case highlights the vigilance for hypokalemia required when mifepristone is given for improving glucose control.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>Mifepristone,Cushing’s Syndrome,Rhabdomyolysis,Acute Kidney Injury,Hypokalemia</Keywords>
      <URLs>
        <Abstract>https://jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=15800&amp;title=Mifepristone-Induced Hypokalemia Causing Rhabdomyolysis and Severe Acute Kidney Injury: A Case Report</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References>Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med 2009; 361: 62-72.&#13;
&#13;
Brown DR, East HE, Eilerman BS, Gordon MB, King EE, Knecht LA, Salke B, Samson SL, Yuen KCJ, Yau H. Clinical management of patients with Cushing syndrome treated with mifepristone: consensus recommendations. Clin Diabetes Endocrinol 2020; 6: 18.&#13;
&#13;
Chavez LO, Leon M, Einav S, Varon J. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care 2016; 20: 135.&#13;
&#13;
Danaei B, Sharifi A, Mazloom H, Najafi I, Farhang Ranjbar M, Safari S. Prevalence of Compartment Syndrome and Disseminated Intravascular Coagulation following Rhabdomyolysis; a Systematic Review and Meta-Analysis. Arch Acad Emerg Med 2023; 11: e55.&#13;
&#13;
Dand;iacute;az-Land;oacute;pez EJ, Villar-Taibo R, Rodriguez-Carnero G, Fernandez-Pombo A, Garcia-Peino R, Blanco-Freire MN, Pena-Dubra A, Prado-Moraand;ntilde;a T, Fernand;aacute;ndez-Xove I, Pand;eacute;rez-Band;eacute;liz E, Cameselle-Teijeiro JM, Hermida-Ameijeiras A, Martinez-Olmos MA. Should we suspect primary aldosteronism in patients with hypokalaemic rhabdomyolysis? A systematic review. Front Endocrinol (Lausanne) 2023; 14: 1257078.&#13;
&#13;
Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER, Monder C. Localisation of 11 beta-hydroxysteroid dehydrogenase--tissue specific protector of the mineralocorticoid receptor. Lancet 1988; 2: 986-989.&#13;
&#13;
Engel AG, Lambert EH, Rosevear JW, Tauxe WN. Clinical And Electromyographic Studies in A Patient with Primary Hypokalemic Periodic Paralysis. Am J Med 1965; 38: 626-640.&#13;
&#13;
Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C; SEISMIC Study Investigators. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushingand;#39;s syndrome. J Clin Endocrinol Metab 2012; 97: 2039-2049.&#13;
&#13;
Funder JW. Mineralocorticoid receptors: distribution and activation. Heart Fail Rev 2005; 10: 15-22.&#13;
&#13;
Gunal AI, Celiker H, Dogukan A, Ozalp G, Kirciman E, Simsekli H, Gunay I, Demircin M, Belhan O, Yildirim MA, Sever MS. Early and vigorous fluid resuscitation prevents acute renal failure in the crush victims of catastrophic earthquakes. J Am Soc Nephrol 2004; 15: 1862-1867.&#13;
&#13;
Hsu YM, Guidotti G. Effects of hypokalemia on the properties and expression of the (Na+,K+)-ATPase of rat skeletal muscle. J Biol Chem 1991; 266: 427-433.&#13;
&#13;
Huerta-Alardand;iacute;n AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians. Crit Care 2005; 9: 158-169.&#13;
&#13;
Khan FY. Rhabdomyolysis: a review of the literature. Neth J Med 2009; 67: 272-283.&#13;
&#13;
Knochel JP, Schlein EM. On the mechanism of rhabdomyolysis in potassium depletion. J Clin Invest 1972; 51: 1750-1758.&#13;
&#13;
Kruijt N, van den Bersselaar LR, Kamsteeg EJ, Verbeeck W, Snoeck MMJ, Everaerd DS, Abdo WF, Jansen DRM, Erasmus CE, Jungbluth H, Voermans NC. The etiology of rhabdomyolysis: an interaction between genetic susceptibility and external triggers. Eur J Neurol 2021; 28: 647-659.&#13;
&#13;
Lim AK. Abnormal liver function tests associated with severe rhabdomyolysis. World J Gastroenterol 2020; 26: 1020-1028.&#13;
&#13;
Lowe DA, Richardson NP, Taylor P, Donatsch P. Increasing intracellular sodium triggers calcium release from bound pools. Nature 1976; 260: 337-338.&#13;
&#13;
Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A; Endocrine Society. Treatment of Cushingand;#39;s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100: 2807-2831.&#13;
&#13;
Oshima Y. Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. Food and Drug Administration. Intern Med 2011; 50: 845-853.&#13;
&#13;
Qiang W, Song S, Chen T, Wang Z, Feng J, Zhang J, Guo H. A rare case of ectopic ACTH syndrome with rhabdomyolysis. BMC Endocr Disord 2021; 21: 98.&#13;
&#13;
Sever MS, Erek E, Vanholder R, Kantarci G, Yavuz M, Turkmen A, Ergin H, Tulbek MY, Duranay M, Manga G, Sevinir S, Lameire N; Marmara Earthquake Study Group. Serum potassium in the crush syndrome victims of the Marmara disaster. Clin Nephrol 2003; 59: 326-333.&#13;
&#13;
Shi P, Wang C, Lyu Y. Primary aldosteronism with hypokalemic rhabdomyolysis: a case report and review of the literature. J Med Case Rep 2024; 18: 362.&#13;
&#13;
Spergel G, Schmidt P, Stern A, Bleicher SJ. Effects of hypokalemia on carbohydrate and lipid metabolism in the rat. Diabetes 1967; 16: 312-318.&#13;
&#13;
Zutt R, van der Kooi AJ, Linthorst GE, Wanders RJ, de Visser M. Rhabdomyolysis: review of the literature. Neuromuscul Disord 2014; 24: 651-659.</References>
      </References>
    </Journal>
  </Article>
</ArticleSet>